Gender
All
Age Group
18 Years to 60 Years
Accepting Healthy Volunteers
No
Inclusion Criteria:
- Highly sensitized patient cPRA 99-100% AND actively listed for kidney
transplantation at the kidney transplantation Program at University fo Chicago
- Ebstein Barr Virus (EBV) Immunoglobulins (IgG) seropositive
- No active systemic infection
- No allergy to proteasome inhibitors (Bortezomib), or to belatacept
- No known malignancy in the previous 2 years except for non-melanomatous skin cancer
- Female who agrees to practice 2 effective methods of contraception through 3 months
after the last dose of Bortezomib
- Patient vaccinated against hepatitis B virus with positive level of HBsAb
- Patients fully vaccinated against Coronavirus Disease 2019 at least 2 weeks prior to
the start of the 1st cycle.
- Actively listed for kidney transplant at the Transplant Institute at University of
Chicago
Exclusion Criteria:
- Patient with significant neuropathy by the Common Terminology Criteria for Adverse
Events (CTCAE) criteria within 14 days before enrollment (Grades 3-4 or Grade 2 with
pain)
- Myocardial infarction within 6 months of enrollment or has Heart Failure in acute
dialysis quality initiative (ADQI) ESRD classification system Class 2 non
restrictive (2NR) or greater, uncontrolled angina, severe uncontrolled ventricular
arrhythmias, or ECG evidence of acute ischemia or active conduction system
abnormalities
- Patient who received other investigational drugs within 14 days prior to initiation
of study treatment
- Receipt of a live vaccine within 4 weeks prior to initiation of study treatment
- Evidence of severe liver disease by history or physical exam or with abnormal liver
profile ( > 1.5 times upper limit of normal within 30 days of consent)
- Female who is breast feeding or pregnant
- Untreated latent tuberculosis
- History of Post Transplant Lymphoproliferative Disease (PTLD)
- Patient still carrying previous kidney transplant.
